ReviewCurrent oncology reports2006
Current and emerging treatment approaches for tobacco dependence.
Review in Current oncology reports, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 12 citations in OpenAlex.
- The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability.The international journal of neuropsychopharmacology · 2016Article
- New mechanisms and perspectives in nicotine withdrawal.Neuropharmacology · 2015Review
- Role of the Neuregulin Signaling Pathway in Nicotine Dependence and Co-morbid Disorders.International review of neurobiology · 2015Review
- Counseling the patient with potentially HPV-related newly diagnosed head and neck cancer.Current oncology reports · 2014Review
- The role of fatty acid amide hydrolase inhibition in nicotine reward and dependence.Life sciences · 2013Review
- Animal models of nicotine exposure: relevance to second-hand smoking, electronic cigarette use, and compulsive smoking.Frontiers in psychiatry · 2013Article
- Robust escalation of nicotine intake with extended access to nicotine self-administration and intermittent periods of abstinence.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2012Article
- Usage patterns of stop smoking medications in Australia, Canada, the United Kingdom, and the United States: findings from the 2006-2008 International Tobacco Control (ITC) Four Country Survey.International journal of environmental research and public health · 2011Article
- Does the number of free nicotine patches given to smokers calling a quitline influence quit rates: results from a quasi-experimental study.BMC public health · 2010Article
- Differential role of nicotinic acetylcholine receptor subunits in physical and affective nicotine withdrawal signs.The Journal of pharmacology and experimental therapeutics · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nicotine in tobacco is the primary reason why most people find it hard to stop using tobacco. Nicotine creates dependence by activating the dopaminergic reward system in the brain. Physiologic withdrawal symptoms that occur when nicotine is no longer administered reinforce continued nicotine administration to avoid withdrawal. Extrapolating from this evidence has led to the development of tobacco dependence pharmacotherapy based upon the concept of replacing and/or blocking the effects of nicotine in the brain. The efficacy of nicotine replacement and blockade treatments in lessening symptoms of nicotine withdrawal and increasing quit rates has been consistently demonstrated in clinical trials. Despite the availability of efficacious medications to treat nicotine dependence, current therapies remain underutilized across the population. Health-care providers need to systematically encourage all tobacco users to quit and ensure that their tobacco-using patients use evidence-based treatments when they attempt to quit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.